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Developing carriers of active ingredients with pre-determined release kinetics is a
main challenge in the field of controlled release. In this work, we fabricate designer
microparticles as carriers of active ingredients using droplet microfluidics. We show
that monodisperse droplet templates do not necessarily produce monodisperse
particles. Magnetic stirring, which is often used to enhance the droplet solidification
rate, can promote breakup of the resultant microparticles into fragments; with an
increase in the stirring time, microparticles become smaller in average size and more
irregular in shape. Thus, the droplet solidification conditions affect the size, size
distribution and morphology of the fabricated particles, and these attributes of the
microparticles strongly influence their release kinetics. The smaller the average size
of the microparticles is, the higher the initial release rate is. The release kinetics of
drug carriers is strongly related to their characteristics. The understanding of this
relationship enables the fabrication of tailor-designed carriers with a specified release
rate, and even programmed release to meet the needs of applications that require a
complex release profile of the active ingredients. VC 2012 American Institute of
Physics. [http://dx.doi.org/10.1063/1.4738586]
INTRODUCTION
An emulsion is a mixture of two immiscible liquids, in which one liquid is dispersed in the
form of droplets in another liquid that forms the continuous phase. They are frequently used as
a precursor to fabricate particles or capsules for industrial applications. In particular, emulsion-
based delivery systems designed for the encapsulation, protection and release of drugs and other
active ingredients, are of increasing interest to pharmaceutical research and other biomedical
applications. Among these systems, polymer micro/nanoparticles are promising vehicles due to
their potential to release active ingredients in a controlled manner.1–9 To prepare polymer
micro/nanoparticles, the polymer and the drug are first dissolved in an organic solvent to form
the dispersed, droplet phase. This phase is then mixed with an aqueous continuous phase to
form an oil-in-water emulsion. As a final step, the emulsion droplets are solidified to form poly-
mer micro/nanoparticles with drugs encapsulated in the resultant polymer matrix. To solidify
the droplets, the organic solvent has to be removed. Moreover, for most biomedical applications
the organic solvent is often harmful. Therefore, the solvent removal step is critical. Among typ-
ical solvent removal methods, including evaporation, lyophilization, reverse extraction, precipi-
tation, and dialysis (solvent exchange), evaporation is frequently used due to its simplicity.10
Under room conditions, evaporation proceeds relatively slowly; to enhance the rate of particle
production, the precursor emulsions are often mechanically agitated to increase the effective
air/solvent interfacial area, leading to faster solvent evaporation. Besides, with conventional
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emulsion techniques, mechanical agitation also helps to introduce the shear to emulsify the im-
miscible liquids involved, and prevent the droplets from undesired coalescence. However, me-
chanical agitation does not provide exquisite control over the characteristics of formed droplets,
such as droplet size and size distribution. Hence, the characteristics of the resultant polymer
particles are also not precisely controlled.
Recently, developments in droplet microfluidics enable the generation of monodisperse and
size-controlled single/multiple emulsion droplets.11–20 This provides a unique opportunity to fab-
ricate monodisperse and size-controlled polymer micro/nanoparticles for controlled release study.
However, monodisperse polymer particles are not always observed. This is mainly because the
subsequent solvent evaporation and droplet solidification step, usually in the form of mechanical
agitation, can disturb the droplet templates and distort the shape and size uniformity of the
resultant solid particles. The solvent evaporation step can also affect the surface morphology
and other characteristics, such as encapsulation efficiency.21 This effect of the solvent evapora-
tion step on the properties of the resultant particles has yet to be systematically studied.
In this work, we take advantage of monodisperse oil-in-water emulsion droplet templates
produced using microfluidic techniques, and investigate the effect of the droplet solidification
step alone on the characteristics of the resultant drug-loaded poly (lactic-co-glycolic acid)
(PLGA) microparticles, such as size and release kinetics. We demonstrate that monodispersity
of the droplet templates does not guarantee the uniformity of the final microparticles. Mechani-
cal agitation introduced during the solidification process raises the polydispersity of the final
PLGA microparticles; this significantly affects the release characteristics of the PLGA micro-
particles. We further explore the relationship between size and release kinetics of the final
microparticles as drug carriers. Our results provide guidelines on how to tune fabrication condi-
tions for fabricating microparticles with appropriate characteristics for the target applications.
EXPERIMENT SECTION
We use a capillary microfluidic device to generate monodisperse oil-in-water single
emulsions.11–20 In a typical capillary microfluidic single-emulsion device, two cylindrical capil-
laries (World Precision Instrument Inc.), which have an inner diameter and an outer diameter
of 0.58mm and 1mm, respectively, are tapered using a micropipette puller (P-97, Sutter Instru-
ment, Inc.). The tips of the capillaries are polished to desired diameters using a sand paper.
Typical tip diameters of the injection and collection capillaries are 25 lm and 100 lm, respec-
tively. Then, the polished round capillaries are coaxially aligned inside a square capillary (AIT
glass). The device is used for generating monodisperse oil-in-water single emulsions.
To prepare the emulsion templates, we use dichloromethane (DCM) with 8% (w/v) PLGA
(50:50) and 0.8% (w/v) rifampicin as the oil dispersed phase. In this study, we choose rifampi-
cin, which is a drug for treating tuberculosis and can potentially be benefited from the
approach, as a model to investigate the encapsulation and controlled release of active ingre-
dients. PLGA, a common material in drug encapsulation and controlled release study, is known
for its excellent biocompatibility and tunable degradability.5–9 DCM is a frequently used or-
ganic solvent for PLGA and evaporates quickly at room temperature. The aqueous continuous
phase consists of deionized water with 1% (w/v) poly(vinyl alcohol) (PVA), which is added as
a surfactant to prevent oil droplets from coalescence.
The oil dispersed phase is pumped through one round capillary, which is known as the
injection capillary. The aqueous continuous phase flows in the opposite direction through the
region between the other round capillary, often known as the collection capillary, and the outer
square capillary. The resultant jet breaks up into monodisperse oil-in-water (O/W) single-
emulsion drops at the orifice of the collection capillary. The flow rates of the dispersed and the
continuous phases in all experiments are fixed at 800 and 2000ll/h, respectively.
After collection, the emulsion droplets are magnetically stirred to enhance the evaporation
of DCM in the oil droplets. After complete evaporation of DCM, the emulsion droplets are sol-
idified to form PLGA microparticles with drugs encapsulated in the resultant polymer matrix.
To investigate the effect of the extent of stirring, we stir the emulsions magnetically (IKA) at
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different rotational speeds of 100 rpm and 800 rpm, respectively, for different lengths of time.
At 100 rpm, the corresponding energy outputs for stirring time of 2.5 h, 15 h, 22 h, and 45 h are
0.72 kJ, 4.32 kJ, 6.34 kJ, and 13.25 kJ, respectively; whereas, at 800 rpm, the corresponding
energy outputs are 5.76 kJ, 34.56 kJ, 50.69 kJ, and 106.0 kJ, respectively. A schematic illustra-
tion of the experimental set-up is shown in Figure 1(a). For the purpose of comparison, we also
evaporate the solvents without stirring under room temperature for at least 2 days to make sure
all DCM has been evaporated and the PLGA particles are completely solidified.
The morphology of the resultant PLGA microparticles is characterized using an optical micro-
scope (Nikon Eclipse 80i) and a scanning electron microscope (Hitachi S3400N VP SEM). To
obtain the size distribution of the microparticles, we measure at least 100 microparticles for each
diameter by analyzing microscope images using the open-source image analysis software, Image J.
To investigate the in vitro drug release profile of drug-loaded PLGA microparticles, PLGA
microparticles that had been loaded with 1mg rifampicin were dispersed in 1ml phosphate-
buffered saline (PBS) solution (pH 7.4) in centrifuge tubes and shaken at 90 rpm at 37 C. At
each predetermined time interval, dispersions were centrifuged and 200ll of supernatants were
collected. The supernatants were then filtered and assayed by UV method at 473 nm with a
microplate reader. The PBS solution was replaced with fresh solution at each time point after
assaying the rifampicin.
RESULTS AND DISCUSSION
We produce monodisperse oil-in-water single emulsion droplets continuously using droplet
microfluidic devices shown in Figure 1(b). We control the size of droplets produced by chang-
ing the flow rates of the phases and the geometry of the capillary device. The size of the oil
droplet increases with increasing inner phase flow rate, increasing diameter of injection and col-
lection capillary tips, and with decreasing continuous phase flow rate.22–24 The monodisperse
emulsion droplet templates with diameters of about 60 lm are shown in Figure 1(c). The size
uniformity of the droplet templates represents the maximum uniformity that the resultant micro-
particles can have. The emulsion templates are often stirred to enhance the rate of solvent
FIG. 1. (a) Schematic of experimental setup; (b) microfluidic generation of monodisperse oil-in-water single emulsion
droplets; (c) typical monodisperse droplet templates produced using capillary microfluidic devices (enhanced online).
[URL: http://dx.doi.org/10.1063/1.4738586]
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evaporation. As conventional emulsion techniques typically rely on turbulent mixing for emulsi-
fying the precursor solution, the resultant emulsion templates tend to be polydisperse in size.
Therefore, the stirring step, which may break up the emulsion templates, does not significantly
alter the size distribution of the final microspheres. As a result, the effect of the stirring condi-
tions on the size distribution of the resultant microspheres is rarely studied. However, with the
advent of microfluidic emulsification, the emulsion templates can achieve a narrow size distri-
bution; the extent of stirring during the solidification process raises the polydispersity of the
final microparticles, as illustrated schematically in Figure 2; this change in size and size distri-
bution of the microparticles significantly affects their release characteristics.
In our work, although monodisperse PLGA/DCM-in-water emulsion droplets are produced
using droplet microfluidics, polydisperse PLGA microparticles are observed after magnetic
stirring is applied to promote solvent evaporation. There are two possible routes by which the
polydispersity increases, as schematically illustrated in Figure 3(a). First, shear introduced by
the magnetic stirrer may lead to simultaneous coalescence and break-up of droplets before
particles are formed, thus disrupting the size distribution of the droplet templates. Thus, the
resultant microspheres are polydisperse. Second, the magnetic stirring can continue to break
down the solidified polymer microparticle; thus, the final products will be not only polydisperse
in size, but also fragmented in shape. The difference between these two routes can be identified
by the shape of the particles. In our experiments, polydisperse fragmented microparticles are
observed. To confirm the second route, we solidify monodisperse PLGA/DCM droplets under
room temperature without any stirring, and the resultant PLGA microspheres are monodisperse.
The diameter of these microspheres is about 34.2lm with a standard deviation of 1.75, as
shown in Figures 3(b) and 3(c). This indicates that the droplet have shrunken by nearly 60%
after solvent evaporation. Then, we stir a suspension of these monodisperse microspheres using
a magnetic stirrer. After stirring for 2.5 h, indeed, polydisperse fragmented microparticles are
observed; the average diameter of these polydisperse microparticles is 19.9 lm with a standard
deviation of 14.9, as shown in Figure 3(d). This confirms that microparticles can be broken up
into small fragments even after solidification. Therefore, minimal stirring should be used if
monodisperse microspheres are desired.
To investigate the effect of the extent of stirring, we separately vary the stirring speed and
the stirring time during fabrication of the particles. From our observations, varying stirring speed
does not significantly affect the morphology of microparticles. However, when stirring time
is increased, the fraction of broken PLGA microparticles increases, as shown in Figure 4(a). With
FIG. 2. Schematic showing the effect of solvent evaporation on the particle size and size distribution with bulk emulsifica-
tion techniques (top) and droplet microfluidics (bottom).
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a further increase in stirring time, the PLGA particles become more irregular in shape and smaller
in size, as shown in Figure 4(b). Noticeably, after 46 h of stirring, only fragmented pieces of
PLGA polymers are left, as shown in Figure 4(c). Since all microparticles become fragmented
pieces as stirring time is increased, the polydispersity of microparticles appears to have decreased.
As a result, the average size and standard deviation of microparticles decrease with the increase
of stirring time, as shown by the plot in Figure 4(d). These results suggest that the breakup of the
solidified particles while being stirred is the major factor in affecting the size and size distribution
of the final particles.
FIG. 3. (a) Schematic of two possible routes by which the polydispersity of microparticles increases; (b) optical micro-
scope image and (c) SEM image of monodisperse microspheres formed by solvent evaporation from emulsion droplet tem-
plates without stirring; (d) optical microscope images of suspensions of monodisperse solidified microspheres stirred at
100 rpm.
FIG. 4. Optical microscope images of microparticle suspensions stirred at (a) 800 rpm for 2.5 h, (b) 15 h, (c) 46 h, (d) a plot
of the average diameter of PLGA microparticles (with the error bars denoting a standard deviation for each data point) as a
function of stirring time using a magnetic stirrer.
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When microparticles are used for drug encapsulation, the release kinetics of the drug from
the particles should depend critically on their morphology. To investigate the effect of the fabri-
cation conditions on the release kinetics of the microparticles, we encapsulate a drug, rifampi-
cin, as a model compound in the microparticles that are prepared under different conditions; we
measure their release kinetics subsequently. The drugs are distributed and physically trapped in
the PLGA polymer matrices.25–27 The encapsulation of drugs in PLGA microparticles can
extend the release time of the drug and provide a relatively long-term therapeutic effect. There-
fore, it is particularly advantageous for drugs used in treatment of chronic diseases, such as
rifampicin. Although rifampicin is chosen as a model in our study, our results should be appli-
cable to other drugs with similar entrapment mechanisms.
Typically, the release of drug from PLGA microparticles follows a triphasic release pattern
as shown in Figure 5(a).28 Drugs encapsulated inside the PLGA microspheres are released from
the surface of microspheres at the beginning; this usually leads to an initial burst release. After
that, the drugs diffuse continuously from the interior of the microsphere to the surroundings, lead-
ing to a phase with a relatively sustained release at a relatively low concentration. At the end of
the cycle, the PLGA polymer matrix starts to degrade, leading to a second phase of burst release.
The proposed underlying mechanism is illustrated in Figure 5(b). Indeed, the release results from
PLGA microparticle suspensions stirred at 800 rpm for 15 and 46 h have the characteristic release
profiles. They differ mainly in the initial burst release rate, and overall rate of release, as shown
in Figure 5(a). During day 1, microparticle suspensions stirred at 800 rpm for 15h have about 2%
of the drug released; while microparticle suspensions stirred at 800 rpm for 46 h have released
14.1%6 0.4% of the total drug content. Moreover, for microparticle suspensions stirred at
800 rpm for 46 h, 25% of the drugs are released within the first 3 days; for microparticle suspen-
sions stirred at 800 rpm for 15 h, it takes 15 days to release the same fraction of drug. This indi-
cates that the extent of stirring influences the release kinetics of PLGA microparticles.
As in the case of the microparticle morphology, changing the stirring speed has a very
weak effect on the release kinetics of the microparticles. Suspensions of microparticles stirred
FIG. 5. (a) A plot of rifampicin release rate as a function of time; (b) schematic illustration of a proposed release mecha-
nism of drugs from PLGA microparticles as drug carriers.
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at different speeds for the same period of time show similar release profiles, as shown by the
drug release curves in Figure 6.
However, as the morphology of the microparticles depends strongly on the stirring time,
the drug encapsulation efficiency and release kinetics of rifampicin-loaded PLGA microparticles
also depend critically on the stirring time. As the stirring time increases, the microparticles
breaks up into fragments, drugs that are encapsulated inside the microparticles are gradually
released from the broken microparticles to the surroundings. Thus, the efficiency of the result-
ant PLGA microparticles decreases, as shown in Figure 7(a). The drug encapsulation efficiency
for suspensions of microparticles that have been stirred for 46 h decreases by 50%, when com-
pared to that of microparticles stirred for 2.5 h. Although prolonged stirring time leads to low
FIG. 6. Release rate of rifampicin from microparticles fabricated at different stirring speeds for the same period of time.
FIG. 7. (a) A plot of drug encapsulation efficiency as a function of stirring time; (b) initial drug release rate of rifampicin
from microparticles fabricated using the same stirring speed for different periods of time; (c) cumulative percentage of
rifampicin released from microparticles fabricated by stirring for different periods of time.
034104-7 Kong et al. Biomicrofluidics 6, 034104 (2012)
Downloaded 01 Mar 2013 to 147.8.230.143. Redistribution subject to AIP license or copyright; see http://bmf.aip.org/about/rights_and_permissions
drug encapsulation efficiency, it generates microparticles with small average size and thus dis-
tinct release kinetics.
Polydisperse microparticles with a small average size have a very high initial drug release
rate, as shown in Figure 7(b); consequently, most of the drug encapsulated is released initially.
For microparticle suspensions stirred for 46 h, almost 50% of rifampicin is released within the
first 13 days. As the average size of the microparticles increases, the initial drug release is
reduced and most of the drug encapsulated is released at a later stage, as shown in Figure 7(c).
For microparticle suspensions stirred for 2.5 h, only 10% of rifampicin is released within the
first 13 days, and another 55% of rifampicin is released in the following 11 days. The result
indicates that size of microparticles has a significant influence on their release kinetics. Gener-
ally, for microparticles with a smaller diameter, the initial burst release is high and thus a large
amount of the drugs are released at an early stage; for microparticles with larger diameter, drug
release rate is relatively low at the beginning and becomes faster later on. This behavior can be
understood as the relative contributions of release through diffusion from the surface of the
microparticles and through the degradation of the polymer microparticles, as illustrated in
Figure 5(b). For larger microparticles, the surface area-to-volume ratio is lower; thus, the
release through diffusion from the particle surface takes place at a relatively low rate. There-
fore, a large fraction of the drug remains encapsulated inside the microparticles. However, as
the polymer microparticles degrade, the diffusion of the drugs through the particle is sped up,
thus raising the subsequent release rate. Our results provide important guidelines for fabricating
appropriate microparticles for the target applications. The characteristics of microparticles, such
as size, size distribution, and morphology is strongly related to their release kinetics, when they
are used as carriers of active ingredients. By understanding this relationship, we can tailor-
design delivery vehicles with a specified release rate, and program the release of active ingre-
dients to meet the needs of applications that require a complex release profile.
CONCLUSION
Solvent evaporation is critical in the fabrication of microspheres for encapsulation applica-
tions. Solvent evaporation conditions significantly affect the size, size distribution, morphology,
as well as release kinetics of the fabricated particles. We show that magnetic stirring produces
polydisperse microparticles from monodisperse droplet templates; with an increase in stirring
time, microparticles become more irregular in shape and smaller in average size. In comparison
to the stirring time, stirring speed has a weak effect on the attributes of the microparticles. The
morphology of the microparticles has an important effect on their release kinetics. Polydisperse
rifampicin-loaded PLGA microparticles with a small average size have a high initial drug
release rate, while, for microparticles with a larger average size, most of the rifampicin is
released at a later stage. Our results provide important guidelines on how to tune fabrication
conditions to fabricate appropriate microparticles for applications. Due to the limitation of cur-
rent approach of fabricating microparticles, initial burst release is hard to avoid. A new class of
drug carriers with a different structure should be designed and fabricated to achieve zero-order
release for applications that require a long and sustained therapeutic effect. Nevertheless, our
results show that the release kinetics of drug carriers is strongly related to their preparation con-
ditions and morphologies. By understanding the relationship between the drug carrier character-
istics and their release kinetics, tailor-designed drug carriers with pre-determined release rates
that meet the needs of specific applications can be fabricated.
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